| scholarly article | Q13442814 |
| P2093 | author name string | Miriam Reuschenbach | |
| Nikolaus Freudenberg | |||
| Andreas Clad | |||
| Janina Rahmsdorf | |||
| Johanna Weinschenk | |||
| Ruth Grote | |||
| P2860 | cites work | Overview of the European and North American studies on HPV testing in primary cervical cancer screening | Q57414808 |
| Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? | Q71920501 | ||
| Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis | Q74054465 | ||
| Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions | Q77568726 | ||
| Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types | Q78519639 | ||
| Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions | Q80345092 | ||
| HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN | Q80686680 | ||
| Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial | Q83938901 | ||
| Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets | Q84341096 | ||
| Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
| Human papillomavirus and Papanicolaou tests to screen for cervical cancer | Q34702284 | ||
| Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions | Q34995358 | ||
| Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies | Q36644814 | ||
| 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests | Q36955449 | ||
| Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears | Q37310663 | ||
| High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. | Q38306077 | ||
| Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction | Q40495720 | ||
| Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study | Q43769391 | ||
| Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring | Q44574224 | ||
| Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening | Q46570221 | ||
| The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix | Q47201323 | ||
| Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study | Q47779516 | ||
| Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. | Q50676894 | ||
| A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. | Q53333956 | ||
| Human papillomavirus types 16 and 18 mRNA levels and not DNA levels may be associated with advancing stages of cervical cancer. | Q54450351 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1071-1076 | |
| P577 | publication date | 2010-12-29 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology | |
| P478 | volume | 49 |
| Q26776336 | A review of the clinical performance of the Aptima HPV assay |
| Q91688493 | Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis |
| Q90987623 | Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women |
| Q37546570 | Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid |
| Q41633856 | Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology |
| Q55003928 | Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens. |
| Q94453593 | Detection of high-risk human papillomavirus RNA in urine for cervical cancer screening with HPV 16 & 18/45 genotyping |
| Q37496183 | Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening |
| Q37713738 | Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay |
| Q45903948 | Effectiveness of HPV 16 viral load and the E2/E6 ratio for the prediction of cervical cancer risk among Chinese women. |
| Q89666353 | HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review |
| Q54247283 | HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women. |
| Q36856284 | HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease |
| Q35868702 | Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany |
| Q36675236 | Human Papillomavirus Laboratory Testing: the Changing Paradigm |
| Q37909359 | Human papillomavirus testing and genotyping in cervical screening |
| Q24198236 | Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions |
| Q47573484 | Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study |
| Q88804925 | Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology |
| Q34273090 | Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology |
| Q39177983 | Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions |
| Q61795800 | Prevention of Cervical Cancer |
| Q40043990 | Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening. |
| Q37264271 | Stability of cervical specimens in SurePath medium for human papillomavirus testing with the Roche cobas 4800 assay |
| Q38011639 | The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy |
| Q37470374 | The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening |
| Q34330297 | The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies |
| Q35108590 | Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study |
| Q54559907 | [Precancerous lesions of the cervix. Biomarkers in cytological diagnosis]. |
Search more.